Synonym
Falintolol oxalate; (E)-falintolol oxalate; 62NN1Y9V7S; FALINTOLOL OXALATE, (Z)-; Q27271705
IUPAC/Chemical Name
(E)-1-cyclopropylethan-1-one O-(3-(tert-butylamino)-2-hydroxypropyl) oxime oxalate
InChi Key
JQIUFMLMJHPYPY-KYIGKLDSSA-N
InChi Code
InChI=1S/C12H24N2O2.C2H2O4/c1-9(10-5-6-10)14-16-8-11(15)7-13-12(2,3)4;3-1(4)2(5)6/h10-11,13,15H,5-8H2,1-4H3;(H,3,4)(H,5,6)/b14-9+;
SMILES Code
OC(=O)C(O)=O.C\C(C1CC1)=N/OCC(O)CNC(C)(C)C
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
318.37
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Andermann G, Guggenbuhl P, de Burlet G, Himber J. Pharmacokinetics of falintolol II. Absorption, distribution and elimination from tissues and organs following ocular administration and intravenous injection of falintolol in albino rabbits. Methods Find Exp Clin Pharmacol. 1989 Dec;11(12):747-54. PMID: 2576299.
2: Himber J, Andermann G, Bouzoubaa M, Leclerc G. Determination of falintolol, a new aliphatic beta-adrenergic antagonist, in whole blood by gas chromatography with electron-capture detection: geometric isomers resolution. J Chromatogr Sci. 1987 Jan;25(1):33-7. doi: 10.1093/chromsci/25.1.33. PMID: 2880859.
3: Himber J, Sallee VL, Andermann G, Bouzoubaa M, Leclerc G, De Santis L. Effects of topically applied falintolol: a new beta-adrenergic antagonist for treatment of glaucoma. J Ocul Pharmacol. 1987 Summer;3(2):111-20. doi: 10.1089/jop.1987.3.111. PMID: 2903204.
4: Himber J, Andermann G, Erhart M, Leclerc G, Bouzoubaa M. In vitro potential measurement, anaesthetic and antimicrobial effects as indicators of beta-blocker toxicity of the cornea. Methods Find Exp Clin Pharmacol. 1985 Apr;7(4):195-201. PMID: 2862314.
5: Conti P, Dallanoce C, De Amici M, De Micheli C, Klotz KN. Synthesis of new delta 2-isoxazoline derivatives and their pharmacological characterization as beta-adrenergic receptor antagonists. Bioorg Med Chem. 1998 Apr;6(4):401-8. doi: 10.1016/s0968-0896(97)10051-7. PMID: 9597184.
6: Bouzoubaa M, Leclerc G, Rakhit S, Andermann G. New chiral and isomeric cyclopropyl ketoxime propanolamine derivatives with potent beta-adrenergic blocking properties. J Med Chem. 1985 Jul;28(7):896-900. doi: 10.1021/jm00145a008. PMID: 2861288.
